Sign inJoin waitlistJoin the waitlist

Lainie Martin

Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania · Perelman School of Medicine at the University of Pennsylvania

Credentials: · · ·

History

Fox Chase Cancer Center
2002–2004
Internal Medicine
Boston University Medical Center
1999–2002
Temple University School of Medicine
1995–1999

Research

Platinum resistance: the role of DNA repair pathways
Review · Clinical Cancer Research · 2008 · First of 3 authors · Corresponding · 612 citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine · 2023 · 405 citations

David O'Malley
14 papers
Kathleen Moore
13 papers
Ursula Matulonis
12 papers
Michael Birrer
11 papers
Heidi Gray
9 papers
Robert Giuntoli
9 papers
RS
Russell Schilder
9 papers
Deborah Armstrong
8 papers
SR
Steven Remmenga
8 papers
Ardeshir Hakam
6 papers
David Gershenson
6 papers
Fiona Simpkins
6 papers

Grants

SPORE in Ovarian Cancer
National Cancer Institute · P50
Project lead · $363.1K · Johns Hopkins University
2018–2024
Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients
National Cancer Institute · R01
Contact PI · $1.3M · Research Inst of Fox Chase Can Ctr
2010–2018

Clinical trials

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 2
Gynecologic Oncology Group
2010–2014
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Principal investigator · Completed · Phase 1, Phase 2
TetraLogic Pharmaceuticals
2010–2014
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Principal investigator · Completed · Phase 1
TetraLogic Pharmaceuticals
2009–2013
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031